PV3B:F EYEPOINT PHARMAC. DL-01

EUR 23.80 0.00 0
Icon

EYEPOINT PHARMAC. DL-01 (PV3B:F) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | F
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 23.80

0.00 (0.00)%

EUR 0.21B

40.00

N/A

N/A

Icon

PV3B:F

EYEPOINT PHARMAC. DL-01 (EUR)
COMMON STOCK | F
EUR 23.80
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

EUR 0.21B

N/A

EUR 23.80

EYEPOINT PHARMAC. DL-01 (PV3B:F) Stock Forecast

N/A

Based on the EYEPOINT PHARMAC. DL-01 stock forecast from 0 analysts, the average analyst target price for EYEPOINT PHARMAC. DL-01 is not available over the next 12 months. EYEPOINT PHARMAC. DL-01’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of EYEPOINT PHARMAC. DL-01 is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, EYEPOINT PHARMAC. DL-01’s stock price was EUR 23.80. EYEPOINT PHARMAC. DL-01’s stock price has changed by -10.53% over the past week, +9.17% over the past month and +634.57% over the last year.

No recent analyst target price found for EYEPOINT PHARMAC. DL-01
No recent average analyst rating found for EYEPOINT PHARMAC. DL-01

Company Overview EYEPOINT PHARMAC. DL-01

EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, includi...Read More

N/A

N/A

144

December

EUR

Germany

Adjusted Closing Price for EYEPOINT PHARMAC. DL-01 (PV3B:F)

Loading...

Unadjusted Closing Price for EYEPOINT PHARMAC. DL-01 (PV3B:F)

Loading...

Share Trading Volume for EYEPOINT PHARMAC. DL-01 Shares

Loading...

Compare Performance of EYEPOINT PHARMAC. DL-01 Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for PV3B:F

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To EYEPOINT PHARMAC. DL-01 (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NOVA:F
Novo Nordisk A/S 0.00 (0.00%) EUR408.54B 40.80 3.51

ETFs Containing PV3B

Symbol Name PV3B's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About EYEPOINT PHARMAC. DL-01 (PV3B:F) Stock

Stock Target Advisor's fundamental analysis for EYEPOINT PHARMAC. DL-01's stock is Neutral.

Unfortunately we do not have enough data on PV3B:F's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on PV3B:F's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on PV3B:F's stock to indicate if its overvalued.

The last closing price of PV3B:F's stock was EUR 23.80.

The most recent market capitalization for PV3B:F is EUR 0.21B.

Unfortunately we do not have enough analyst data on PV3B:F's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains EYEPOINT PHARMAC. DL-01's stock.

As per our most recent records EYEPOINT PHARMAC. DL-01 has 144 Employees.

Sorry we do not have any infomation available on EYEPOINT PHARMAC. DL-01's address.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...